# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Analysis 1.17. Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 17: Any adverse events for induction of remission in UC

|Study or Subgroup|FMT Events|FMT Total|Control Events|Control Total|Weight|M-H, Random, 95% CI|Risk of Bias|
|---|---|---|---|---|---|---|---|
|Březina 2021|12|23|13|22|8.6%|0.88 [0.52 , 1.49]|+ ? - + + + +|
|Costello 2019|7|38|7|35|2.7%|0.92 [0.36 , 2.36]|+ + + + + +|
|Crothers 2021 (1)|2|7|2|8|0.8%|1.14 [0.21 , 6.11]|+ + + + - +|
|Fang 2021|2|10|0|10|0.3%|5.00 [0.27 , 92.62]|+ ? - + + +|
|Haifer 2022|10|15|17|20|14.5%|0.78 [0.52 , 1.17]|+ + + + + +|
|Moayyedi 2015|3|38|2|37|0.8%|1.46 [0.26 , 8.25]|+ + + + + +|
|Pai 2021|10|13|5|12|4.4%|1.85 [0.89 , 3.84]|+ + + - - +|
|Paramsothy 2017|32|41|33|40|50.3%|0.95 [0.76 , 1.17]|+ + + + + +|
|Rossen 2015 (2)|18|23|16|25|17.7%|1.22 [0.85 , 1.76]|+ + + + + +|

Total (95% CI): 208 / 209

Total events: 96 / 95

Heterogeneity: Tau² = 0.00; Chi² = 7.48, df = 8 (P = 0.49); I² = 0%

Test for overall effect: Z = 0.06 (P = 0.95)

Test for subgroup differences: Not applicable

# Footnotes

(1) Reported adverse events "possibly or probably related to FMT."

(2) Reported adverse events "related to FMT."

# Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

# Analysis 1.18. Comparison 1: Fecal microbiota transplantation (FMT) versus control for induction of remission in ulcerative colitis (UC), Outcome 18: Induction of endoscopic remission in UC at longest follow-up

|Study or Subgroup|FMT Events|FMT Total|Control Events|Control Total|Weight|M-H, Random, 95% CI|M-H, Random, 95% CI|Risk of Bias|
|---|---|---|---|---|---|---|---|---|
|Březina 2021 (1)|3|23|3|22|19.5%|0.96 [0.22 , 4.24]| |+ ? - + + + +|
|Costello 2019 (2)|4|38|0|35|7.0%|8.31 [0.46 , 148.95]| |+ + + + + +|
|Haifer 2022|7|15|3|20|25.8%|3.11 [0.96 , 10.08]| |+ + + + + +|
|Paramsothy 2017|5|41|3|40|21.8%|1.63 [0.42 , 6.36]| |+ + + + + +|
|Sarbagili Shabat 2022|5|36|4|15|25.9%|0.52 [0.16 , 1.68]| |+ + + + + +|

Total (95% CI): 153 / 132

Total events: 24 / 13

Heterogeneity: Tau² = 0.32; Chi² = 6.42, df = 4 (P = 0.17); I² = 38%

Test for overall effect: Z = 0.88 (P = 0.38)

Test for subgroup differences: Not applicable

# Footnotes

(1) Endoscopic Mayo score 0 at week 12.

(2) Mayo score < 1 at week 8.

# Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.